CTLA4 and non-small cell lung carcinoma: To date, clinically approved ICIs targeting PD-1/PD-L1 and CTLA-4 have shown promising efficacy and became the standard treatments for various cancers, such as advanced melanoma, NSCLC, and solid tumors with microsatellite instability (2, 12, 19).